Viewing profile — biols
biols
HN member- Joined
- Thu, Mar 14, 2019, 1:51 AM UTC
- HN karma
- 72
- Public activity
- 11 items
- HN profile
- View on Hacker News ↗
About biols
No profile information was provided.
Recent public activity
-
comment
Comment #32396835
Yes!! I and my colleagues and probably everyone I went to graduate school with would love a resource like that. I'd be happy to help promote and/or contribute articles / papers I'm…
-
comment
Comment #32386598
Side question: does anybody know of a Hacker News type aggregator for biotech which isn't fuddy-duddy or paid? Sites like STAT+ and Fierce Biotech usually feel more focused on busi…
-
comment
Comment #31667897
Putting "gay-everything in your face at every corner" next to "obvious hard core drug abuse on the sidewalks" could be misconstrued as homophobic, which I hope wasn't your intentio…
-
comment
Comment #30258418
I'd be very happy to participate in those type of projects. One could even imagine that pharma companies could be _mandated_ to spend a certain number of people-hours on R&D in a r…
-
comment
Comment #30253893
I agree that the system is just "reality" right now. I think the idea of a cryptographic data commons is an interesting idea, I'm just trying to imagine how it'd play out in my day…
-
comment
Comment #30253831
I think the idea would have been that Pfizer and Moderna could have pooled resources and made a single optimal vaccine faster, though I'll admit I'm not sure it could have happened…
-
comment
Comment #30253421
The Broad Institute hosts a very interesting transcriptomic dataset called CMap [1] that was intended to facilitate rapid drug repurposing. Having studied this dataset and worked w…
-
comment
Comment #30253389
This is what I'd like to see. There should be some kind of system where in-progress research being done by pharma companies can be published. This would reduce the massively redund…
-
comment
Comment #30253352
Major pharma companies are all constantly competing, and very often are duplicating work because they are not sharing major experimental results. The way it feels is that there's a…
-
comment
Comment #30251575
I work at a medium-sized pharmaceutical company as a computational biologist. Diseases like KS sometimes come up as potential repurposing targets (or novel drug targets), but we ge…
-
comment
Comment #19385863
There's the 20/20/20 rule (every 20 minutes, look at something 20 feet away for 20 seconds) that's cited often. I started to have similar issues, and my optometrist set me up with …